However an awesome finding on cancer healing research has confirmed that hormone based antitumor drugs can perform tremendously well as an alternative of Chemotherapy in particular cases of cancer. In the United States, breast cancer is the second most common cancer in women after skin cancer, affecting about 230,000 new patients annually. However, many patients also are urged to have chemo, to fight off stray cancer cells that may have spread beyond the breast and could be a root of a new cancer later. Ninety-six of the children were exposed to chemotherapy, 11 were exposed to radiotherapy, 13 were exposed to surgery, two were exposed to drug treatments and 14 had mothers who did not undergo treatment while pregnant.
Advertisement
Sparano was talking about a five-year study created to figure out if certain women could forgo chemotherapy without affecting their chances of recovery from breast cancer. Dr. Clifford Hudis is a field expert from The Memorial Sloan Kettering Cancer Center (New York).
“Every woman diagnosed with breast cancer, one of their first concerns is whether or not they have to do chemo”, says Dr. Marilyn Raymond of Good Samaritan. For now, however, this assay is the most rigorously tested option and provides proof of the principle that we can develop reproducible predictive tests to select patients who should not receive chemotherapy. At the end of the study, less than two percent of the hormone-only group had the cancer spread and the survival rate was 98 percent overall. Results on these groups are not yet ready, as the study is continuing. “Chemotherapy is more likely to harm these patients than to help them”.
The findings were published earlier today, September 28, 2015, in the New England Journal of Medicine. It may be the difference between recovering or not for a few cancer patients, but others do not reap any benefits from the aggressive radiation.
About Oncotype DXThe Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions.
Added Professor Peter Naredi, scientific co-chair of the Congress: “These latest results should be reassuring for pregnant women who have been diagnosed with cancer and who will, naturally, be worrying about the best course of action not only for themselves but for their unborn child. I was thrilled not to have to have it”, and has been fine since then, she said. All of the women’s tumors had features suggesting chemotherapy should be used in treatment, as well as an endocrine therapy such as tamoxifen.
Advertisement
The Oncotype DX test has been available as a laboratory test since 2004, and its $4,175 cost is covered by Medicare and many insurance companies.
